The two companies have communicated the results of phase 3 of a clinical trial carried out in the United States.
Reading time : 1 min.
For the moment, minors are not affected by the campaign vaccine in France, but this data could change the situation. Pfizer and BioNTech announced on Wednesday March 31 that their Covid-19 vaccine was 100% effective in adolescents aged 12 to 15. The two laboratories obtained these results during a clinical trial in the United States.
Phase 3 trials conducted on 2,260 adolescents in the United States “demonstrated 100% efficacy and robust antibody responses”, welcomed the two companies in a press release, adding that they would ask regulators for the approval of the vaccine for adolescents and hoped for a possible use in this category of the population. “before the next school year”.
BioNTech announced on Tuesday that it wanted to manufacture 25% more doses of its vaccine in 2021. This represents up to 2.5 billion doses in addition to the product. Production capacities are expected to increase due to “expansion of the production network” as well as the authorization to draw six doses from a vial, the company explains in a press release.